← All stories
Deals
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
PARIS, FRANCE, 21 AUGUST 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III…
Covered by 1 outlet
All coverage · 1 article